Synaptogenix Inc (SNPX)

[InTheTrenches]

SF:

I agree 100%. If the company in April reports something along the lines of "We met our primary endpoint in both drug arms of our trial of Bryostatin. The drug was well-tolerated, with myalgias treated with analgeisics. We are the first company in the history of drug trials to show improvement in the lives of moderate-to-severe Alzheimer's patients. We look forward to trials of Bryostatin in mild-to-moderate Alzheimer's patients, Fragile X, Rhett's syndrome, etc., etc.", IMO NTRP stock won't trade less than $50/share, but more likely much more. How does retail lose in that scenario?